Gufic BioSciences Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹4,208 Cr
- P/E
- 57.22
- ROE
- 9.98%
- PEG
- -7.67
- Price to sales
- 4.32
- Debt to equity
- 0.61
- 52W high / low
- ₹448 / ₹274
- Sales growth (5Y)
- 14.04%
- EBITDA margin
- 16.91%
- Net profit margin
- 6.71%
- Promoter holding
- 72.50%
- Sales (last year)
- ₹974 Cr
Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.
Guidance scorecard · Q1 FY27 call
What Gufic BioSciences Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
10–20%- Company targets 15% to 20% year-over-year revenue growth as a bare minimum, with efforts ongoing to exceed 20% growth.
- Indore facility capacity utilization is expected to increase from around 30-35% to close to 80% in the next 2-3 years, improving operating leverage.
- Revenue extraction from Indore alone is projected between INR 800 crores to INR 1,200 crores without additional capex.
- Overall revenue potential combining existing product mix and legacy capacity is estimated between INR 1,600 crores to INR 2,000 crores.
- Product mix improvements aiming to increase average revenue per vial from INR 80-100 to INR 300-500 to drive further growth.
- Expansion into complex injectables, depot, and liposomal products expected to contribute 20-30% of production by FY28.
2 more points from Gufic BioSciences Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
Up 2%+See what Gufic BioSciences Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- Current capex around INR 300 crore mainly for Indore and Navsari facilities.
- No major new infrastructure or equipment capex planned; focus is on adding new product lines (depot and liposomal injections) within existing capex.
- Capacity expansion by introducing depot and liposomal products in lyophilization lines.
- Indore plant fully operational; ongoing validation batches for depot and liposomal products.
2 more points from Gufic BioSciences Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Gufic BioSciences Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
- Indore plant's capacity utilization is increasing gradually, expected to reach 40-45% by year-end, indicating growing order inflow.
- Validation batches for new product lines like depot and liposomal injections are ongoing, pointing to future orders.
- International registrations and partnerships are progressing, with efforts to expand export markets (e.g., EU certification pending, U.S. submissions in progress).
- Contract Manufacturing Operations (CMO) for GLP-1 products have started contributing to revenues, expected to grow in coming quarters.
2 more points from Gufic BioSciences Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Gufic BioSciences Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Gufic BioSciences Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Gufic BioSciences Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 215 | 202 | 195 | 203 | 204 | 208 | 205 | 224 | 237 | 231 |
| Expenses + | 176 | 165 | 161 | 167 | 166 | 174 | 179 | 190 | 199 | 198 |
| Operating Profit | 39 | 36 | 34 | 36 | 39 | 34 | 26 | 33 | 38 | 33 |
| OPM % | 18% | 18% | 18% | 18% | 19% | 16% | 13% | 15% | 16% | 14% |
| Other Income + | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 2 | 1 |
| Interest | 4 | 3 | 4 | 5 | 5 | 5 | 8 | 9 | 10 | 8 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 5 | 8 | 8 | 8 | 8 |
| Profit before tax | 31 | 30 | 27 | 28 | 29 | 26 | 11 | 17 | 23 | 18 |
| Tax % | 25% | 25% | 26% | 26% | 26% | 26% | 27% | 24% | 26% | 30% |
| Net Profit + | 23 | 22 | 20 | 21 | 22 | 19 | 8 | 13 | 17 | 12 |
| EPS in Rs | 2.39 | 2.22 | 2.00 | 2.08 | 2.17 | 1.93 | 0.77 | 1.30 | 1.68 | 1.24 |
Financials of Gufic BioSciences Ltd
Profit & Loss
Annual income statement trend
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| Sales + | 807 | 820 | 897 |
| Expenses + | 657 | 684 | 767 |
| Operating Profit | 150 | 136 | 130 |
| OPM % | 19% | 17% | 15% |
| Other Income + | -0 | 4 | 4 |
| Interest | 17 | 25 | 36 |
| Depreciation | 17 | 21 | 31 |
| Profit before tax | 116 | 94 | 68 |
| Tax % | 26% | 26% | |
| Net Profit + | 86 | 70 | 50 |
| EPS in Rs | 8.59 | 6.95 | 4.99 |
| Dividend Payout % | 1% | 1% |
Financials of Gufic BioSciences Ltd
Balance Sheet
Capital structure and asset base
| Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|
| Equity Capital | 10 | 10 | 10 |
| Reserves | 523 | 591 | 621 |
| Borrowings + | 333 | 336 | 369 |
| Other Liabilities + | 227 | 232 | 271 |
| Total Liabilities | 1,093 | 1,169 | 1,271 |
| Fixed Assets + | 159 | 506 | 495 |
| CWIP | 307 | 22 | 24 |
| Investments | 2 | 2 | 2 |
| Other Assets + | 625 | 640 | 750 |
| Total Assets | 1,093 | 1,169 | 1,271 |
Financials of Gufic BioSciences Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Cash from Operating Activity + | -7 | 123 |
| Cash from Investing Activity + | -102 | -71 |
| Cash from Financing Activity + | 82 | -37 |
| Net Cash Flow | -27 | 15 |
| Free Cash Flow | -116 | 52 |
| CFO/OP | 13% | 107% |
Financials of Gufic BioSciences Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 149 | 140 |
| Inventory Days | 188 | 211 |
| Days Payable | 156 | 155 |
| Cash Conversion Cycle | 181 | 197 |
| Working Capital Days | 97 | 93 |
| ROCE % | 13% |
Guidance history
How Gufic BioSciences Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 10–20% | Up 2%+ | Planned | — | — |
| Q4 FY26 call → | 10–20% | Up 0–2% | Planned | Planned | — |
| Q3 FY26 call → | 10–20% | Up 0–2% | Planned | None planned | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
81 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +25.9% | 76% |
| Last 6 months | +47.2% | 88% |
| Last 3 months | +9.1% | 78% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Gufic BioSciences Ltd: 0.4 × 76 + 0.4 × 88 + 0.2 × 78 = 81.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Gufic BioSciences Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q1 FY26 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY